BioCentury
ARTICLE | Clinical News

CHMP recommends Dompe's human nerve growth factor for keratitis

May 26, 2017 5:20 PM UTC

EMA’s CHMP recommended approval of an MAA from Dompe Farmaceutici S.p.A. (Milan, Italy) for Oxervate cenegermin to treat moderate or severe neurotrophic keratitis. The opinion is based on data from 2 Phase II trials in 204 patients showing that Oxervate led to greater complete corneal healing after 8 weeks compared to placebo...

BCIQ Company Profiles

Dompe Farmaceutici S.p.A.